Aceclofenac
The risk or severity of adverse effects can be increased when Aceclofenac is combined with Pamidronate.
Acemetacin
The risk or severity of adverse effects can be increased when Acemetacin is combined with Pamidronate.
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pamidronate.
Advertisement
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Pamidronate.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Pamidronate.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Pamidronate.
Advertisement
Aloglutamol
The serum concentration of Pamidronate can be decreased when it is combined with Aloglutamol.
Aluminum
The serum concentration of Pamidronate can be decreased when it is combined with Aluminium.
Aluminum Hydroxide
The serum concentration of Pamidronate can be decreased when it is combined with Aluminum hydroxide.
Advertisement
aluminum hydroxide, dried (USP)
The serum concentration of Pamidronate can be decreased when it is combined with Aluminum hydroxide.
Aluminum Magnesium Silicate
The serum concentration of Pamidronate can be decreased when it is combined with Almasilate.
Amikacin
Amikacin may increase the hypocalcemic activities of Pamidronate.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Pamidronate.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Pamidronate.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Pamidronate.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Pamidronate.
Arbekacin
Arbekacin may increase the hypocalcemic activities of Pamidronate.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pamidronate.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Pamidronate.
Balsalazide
The risk or severity of adverse effects can be increased when Balsalazide is combined with Pamidronate.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Pamidronate.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Pamidronate.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Pamidronate.
Bismuth Subcitrate
The serum concentration of Pamidronate can be decreased when it is combined with Bismuth Subcitrate.
Bismuth Subnitrate
The serum concentration of Pamidronate can be decreased when it is combined with Bismuth subnitrate.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Pamidronate.
Bufexamac
The risk or severity of adverse effects can be increased when Bufexamac is combined with Pamidronate.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pamidronate.
Calcium Acetate
The serum concentration of Pamidronate can be decreased when it is combined with Calcium Acetate.
Calcium Carbonate
The serum concentration of Pamidronate can be decreased when it is combined with Calcium Carbonate.
CALCIUM CARBONATE, PRECIPITATED
The serum concentration of Pamidronate can be decreased when it is combined with Calcium Carbonate.
Calcium Chloride
The serum concentration of Pamidronate can be decreased when it is combined with Calcium Chloride.
Calcium Chloride Anhydrous
The serum concentration of Pamidronate can be decreased when it is combined with Calcium Chloride.
Calcium Citrate
The serum concentration of Pamidronate can be decreased when it is combined with Calcium Citrate.
Calcium Glubionate
The serum concentration of Pamidronate can be decreased when it is combined with Calcium glubionate.
Calcium gluceptate
The serum concentration of Pamidronate can be decreased when it is combined with Calcium Gluceptate.
Calcium Gluconate
The serum concentration of Pamidronate can be decreased when it is combined with Calcium gluconate.
Calcium Lactate
The serum concentration of Pamidronate can be decreased when it is combined with Calcium lactate.
CALCIUM LEVULINATE
The serum concentration of Pamidronate can be decreased when it is combined with Calcium levulinate.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Pamidronate.
Casein Allergenic Extract
The serum concentration of Pamidronate can be decreased when it is combined with Casein.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Pamidronate.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Pamidronate.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pamidronate.
Clofezone
The therapeutic efficacy of Pamidronate can be decreased when used in combination with Rabeprazole.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Pamidronate.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Pamidronate.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Pamidronate.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Pamidronate.
Deferasirox
The risk or severity of adverse effects can be increased when Pamidronate is combined with Deferasirox.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Pamidronate.
Dexlansoprazole
The therapeutic efficacy of Pamidronate can be decreased when used in combination with Dexlansoprazole.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Pamidronate.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Pamidronate.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Pamidronate.
Digoxin
Digoxin may decrease the cardiotoxic activities of Pamidronate.
Dihydrostreptomycin
Dihydrostreptomycin may increase the hypocalcemic activities of Pamidronate.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Pamidronate.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Pamidronate.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Pamidronate.
Droxicam
The risk or severity of adverse effects can be increased when Droxicam is combined with Pamidronate.
Esomeprazole
The therapeutic efficacy of Pamidronate can be decreased when used in combination with Esomeprazole.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Pamidronate.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Pamidronate.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Pamidronate.
Etoricoxib
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Pamidronate.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Pamidronate.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Pamidronate.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Pamidronate.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Pamidronate.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Pamidronate.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Pamidronate.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pamidronate.
Framycetin
Framycetin may increase the hypocalcemic activities of Pamidronate.
Gentamicin
Gentamicin may increase the hypocalcemic activities of Pamidronate.
Hydrotalcite
The serum concentration of Pamidronate can be decreased when it is combined with Hydrotalcite.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Pamidronate.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Pamidronate.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Pamidronate.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Pamidronate.
Iron Sucrose
The serum concentration of Pamidronate can be decreased when it is combined with Iron saccharate.
Kanamycin
Kanamycin may increase the hypocalcemic activities of Pamidronate.
kanamycin A
Kanamycin may increase the hypocalcemic activities of Pamidronate.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Pamidronate.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pamidronate.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Pamidronate.
Lansoprazole
The therapeutic efficacy of Pamidronate can be decreased when used in combination with Lansoprazole.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Pamidronate.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Pamidronate.
Lornoxicam
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Pamidronate.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Pamidronate.
Magnesium Carbonate
The serum concentration of Pamidronate can be decreased when it is combined with Magnesium carbonate.
Magnesium Hydroxide
The serum concentration of Pamidronate can be decreased when it is combined with Magnesium hydroxide.
Magnesium Oxide
The serum concentration of Pamidronate can be decreased when it is combined with Magnesium oxide.
Magnesium Salicylate
The serum concentration of Pamidronate can be decreased when it is combined with Magnesium salicylate.
Magnesium silicate
The serum concentration of Pamidronate can be decreased when it is combined with Magnesium silicate.
Magnesium Sulfate
The serum concentration of Pamidronate can be decreased when it is combined with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The serum concentration of Pamidronate can be decreased when it is combined with Magnesium sulfate.
Magnesium Trisilicate
The serum concentration of Pamidronate can be decreased when it is combined with Magnesium Trisilicate.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Pamidronate.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pamidronate.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pamidronate.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pamidronate.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Pamidronate.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Pamidronate.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pamidronate.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pamidronate.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pamidronate.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Pamidronate.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Pamidronate.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Pamidronate.
Neomycin
Neomycin may increase the hypocalcemic activities of Pamidronate.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Pamidronate.
Netilmicin
Netilmicin may increase the hypocalcemic activities of Pamidronate.
Niflumic Acid
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pamidronate.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Pamidronate.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Pamidronate.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Pamidronate.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Pamidronate.
Omeprazole
The therapeutic efficacy of Pamidronate can be decreased when used in combination with Omeprazole.
Ouabain
Ouabain may decrease the cardiotoxic activities of Pamidronate.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pamidronate.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Pamidronate.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pamidronate.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pamidronate.
Palmidrol
The risk or severity of adverse effects can be increased when Palmidrol is combined with Pamidronate.
Pantoprazole
The therapeutic efficacy of Pamidronate can be decreased when used in combination with Pantoprazole.
Parecoxib
The risk or severity of adverse effects can be increased when Parecoxib is combined with Pamidronate.
Paromomycin
Paromomycin may increase the hypocalcemic activities of Pamidronate.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Pamidronate.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pamidronate.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pamidronate.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Pamidronate.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Pamidronate.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Pamidronate.
Plazomicin
Plazomicin may increase the hypocalcemic activities of Pamidronate.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Pamidronate.
Rabeprazole
The therapeutic efficacy of Pamidronate can be decreased when used in combination with Rabeprazole.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Pamidronate.
Rofecoxib
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Pamidronate.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Pamidronate.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Pamidronate.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Pamidronate.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Pamidronate.
Sisomicin
Sisomicin may increase the hypocalcemic activities of Pamidronate.
Streptomycin
Streptomycin may increase the hypocalcemic activities of Pamidronate.
Sucroferric Oxyhydroxide
The serum concentration of Pamidronate can be decreased when it is combined with Iron saccharate.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pamidronate.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Pamidronate.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Pamidronate.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Pamidronate.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Pamidronate.
Thalidomide
Thalidomide may increase the nephrotoxic activities of Pamidronate.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pamidronate.
Tobramycin
Tobramycin may increase the hypocalcemic activities of Pamidronate.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pamidronate.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Pamidronate.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Pamidronate.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Pamidronate.
Tribenoside
The risk or severity of adverse effects can be increased when Tribenoside is combined with Pamidronate.
Tricalcium Phosphate
The serum concentration of Pamidronate can be decreased when it is combined with Calcium Phosphate.
Tromethamine
The serum concentration of Pamidronate can be decreased when it is combined with Tromethamine.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Pamidronate.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Pamidronate.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Pamidronate.
